Virbac SA (VIRP.PA) fair value

ACCE thesis

Virbac makes animal health products, mainly veterinary vaccines, parasiticides and pet-care medicines, selling them through its own distribution subsidiaries across Europe, North America, Latin America and Asia. The moat is in the regulatory and channel work: veterinary product approvals take years, and a 67.2% gross margin says the portfolio carries real pricing power rather than commodity economics. The near-term story is steady, not dramatic, with revenue growing 4.0% and operating margin at 18.1%, so the case rests on margin durability and cash conversion rather than a sudden acceleration. At 15.2x forward earnings against 18.8x trailing, the market is pricing in some earnings growth, and a 13.6% ROE shows the business generates decent returns on the equity it holds. It is not in any index we track, which is part of why it merits a look: the coverage gap may be keeping the multiple below where a 67% gross-margin specialist would normally trade. The deeper work is on the pipeline, the pet-care mix and whether recent growth holds outside the company's core European markets.